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mutation in the CSB gene, which
suggests a possible explanation for the
discrepancy in the genotype–phenotype
relationship (Horibata et al., 2004).
Spivak (2005) has demonstrated that
UVSS comprises at least two comple-
mentation groups: UVSS/CS-B, with a
mutation in CSB gene, and UVSS/A,
with a mutation in an unidentified
gene. Two UVSS/CS-B patients, UVSS1-
KO and CS3AM, have been reported to
carry the same CSB mutation, that is,
the nonsense mutation CGA308:Arg77 to
TGA308:stop (Miyauchi-Hashimoto
et al., 1998, K. Tanaka, personal com-
munication).
We propose two possibilities to
explain why patient KPSX6 had CS
symptoms such as neurological ab-
normalities, whereas patients UVSS1KO
and CS3AM did not, despite the
presence of a null mutation of the CSB
gene in KPSX6, UVSS1KO, and CS3AM
cells. First, the transiently produced
mRNA or polypeptides of various
lengths transcribed from the CSB gene
in KPSX6, UVSS1KO, and CS3AM may
reflect a different response to oxidative
stress. Alternatively, patients UVSS1KO
and CS3AM may develop neurological
symptoms in the future. Some neurolo-
gical abnormalities did not appear in
patient KPSX6 until the age of 47 years.
At the time of reporting, patients
UVSS1KO and CS3AM were 33 and
13 years old, respectively. Continued
follow-up of the two patients UVSS1KO
and CS3AM may clarify our hypothesis,
as might further studies focusing on the
response after oxidative stress in CS-B
and UVSS/CS-B cells.
This study was approved by the
medical ethical committee of the Uni-
versity of Kumamoto and was con-
ducted according to the Declaration of
Helsinki Principles. Informed consent
was obtained from patients.
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TO THE EDITOR
Psoriasis is a chronic skin disease with
typical histopathologic findings of epi-
dermal hyperplasia and vascular
changes. Vascular endothelial growth
factors (VEGFs) are potent stimulators of
the angiogenesis affecting endothelial
cell proliferation, motility, and vascular
permeability, and they are crucial
regulators of vascular development
during embryogenesis as well as for
blood vessel formation in adults.
Abbreviations: LD, linkage disequilibrium; SNP, single-nucleotide polymorphism; VEGF, vascular
endothelial growth factor
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Although some studies have indicated
positive correlations between VEGFA
and psoriasis in terms of the mRNA
levels in the lesional skin of psoriasis
(Detmar et al., 1994), single-nucleotide
polymorphisms (SNPs) (Young et al.,
2004; Barile et al., 2006), and trans-
genic mice (Detmar et al., 1998), others
have reported opposing results impli-
cating VEGFA’s role in immune dysre-
gulation with favoring Th2 rather than Th1
(Lee et al., 2004; Park et al., 2006). We
performed an SNP study in psoriasis and
normal controls to investigate the relation-
ship between VEGFs and psoriasis.
We included 243 psoriasis patients
(male:female (M:F)¼ 159:84, age: 41.26±
14.71 years) and 474 normal controls
(M:F¼ 254:220, age: 23.23±2.24 years).
This study was conducted under ap-
proval of the institutional review board
and according to the Declaration of
Helsinki Principles. Written informed
consent was obtained from all the
participants.
Information on the SNPs between
5 kb up- and downstream of four genes
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Figure 1. Map of VEGFA, VEGFC, FIGF, and FLT4 on chromosome 6p12 (21.4 kb), 4q34.1–q34.3 (116.3 kb), Xp22.31 (41.5 kb), and 5q35.3 (53.7 kb),
respectively. Coding exons are marked by black blocks, and the 50- and 30-UTRs are marked by gray blocks. The first base of the translation start site is denoted
as nucleotide þ1. Genotyped polymorphisms in the four genes are marked. Minor allele frequencies of the polymorphism in the 48 samples are distinguished as
over 10% or less. Dots indicate the polymorphisms genotyped in a larger population (n¼ 717). LD among the tag SNPs and their tagged SNPs are presented in r2
and the haplotypes are listed in boxes.
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Table 1. The SNP markers genotyped for the case–control samples (dbSNP build 126)
Gene ID RS number Chr Position Function MAF HWE
VEGFA 4186C/T 9381249 chr6 43842776 Promoter 0.21 0.58
VEGFA 634C/G 2010963 chr6 43846328 Promoter (50UTR) 0.48 0.35
VEGFA IVS2-111A/C 2146323 chr6 43853073 Intron 2 0.25 0.17
VEGFA IVS7-1203A/G 3025033 chr6 43859053 Intron 7 0.18 0.27
VEGFA IVS7-919C/T 3025035 chr6 43859337 Intron 7 0.20 0.39
VEGFA 1561A/G 10434 chr6 43861190 30UTR 0.15 0.59
VEGFC IVS1-26121T/C 4146612 chr4 178052170 Intron 1 0.07 0.16
VEGFC IVS4+8815G/C 3775194 chr4 177999026 Intron 4 0.12 0.29
VEGFC 3641T/C 2046463 chr4 177977848 30UTR 0.36 0.02
FIGF 330G/A 6632528 chrX 15162055 Exon 1 (50UTR) 0.34 0.831
FIGF IVS5-698C/A 6527518 chrX 15125836 Intron 5 0.37 0.971
FLT4 454T/C 1382302 chr5 180009605 Promoter 0.38 0.55
FLT4 IVS1+2240G/A 307814 chr5 180006854 Intron 1 0.35 0.23
FLT4 IVS1+3064G/A 12519726 chr5 180006030 Intron 1 0.42 0.39
FLT4 IVS1-2026G/C 10085109 chr5 179993410 Intron 1 0.28 0.01
FLT4 IVS1-185T/C 2290983 chr5 179991569 Intron 1 0.41 0.003
FLT4 IVS8+694T/C 3797102 chr5 179987794 Intron 8 0.33 0.30
FLT4 IVS8-759G/A 3776413 chr5 179986630 Intron 8 0.15 0.73
FLT4 Y448Y 3736062 chr5 179985552 Exon 10 0.13 0.23
FLT4 IVS10+761G/A 307823 chr5 179984714 Intron 10 0.46 0.14
FLT4 IVS10+882G/A 3797104 chr5 179984593 Intron 10 0.26 0.12
FLT4 IVS13-64G/C 2242213 chr5 179980922 Intron 13 0.10 0.80
FLT4 IVS16-104G/A 382266 chr5 179980018 Intron 16 0.40 0.50
FLT4 P1066P 11949194 chr5 179975994 Exon 23 0.21 0.34
FLT4 IVS23-820C/A 367217 chr5 179974605 Intron 23 0.23 0.15
FLT4 IVS29-220G/A 307833 chr5 179968110 Intron 29 0.24 0.30
FLT4 6293T/C 6879285 chr5 179965491 30UTR 0.40 0.93
FLT4 7811T/C 7709359 chr5 179963973 30UTR 0.36 1.00
FLT4 10435G/A 2279622 chr5 179961349 30UTR 0.19 0.37
FLT4 11901T/G 10065018 chr5 179959883 30UTR 0.14 0.33
FLT4 12506G/C 10055319 chr5 179959278 30UTR 0.49 1.00
HWE, P-values from the w2 test for Hardy–Weinberg equilibrium; MAF, minor allele frequency; UTR, untranslated region.
MAF and HWE are calculated from 474 normal control samples.
1HWE was tested using the female group.
Table 2a. Allelic frequencies of the rs3776413 and rs307823 SNPs in the FLT4 gene between the psoriasis and
normal control groups while adjusting for age and gender
Allele
SNP Group G A OR (95% CI) P-value
rs3776413 PS 383 (0.79) 103 (0.21) 1.61 (1.05,2.47) 0.028
NR 803 (0.85) 145 (0.15)
rs307823 PS 282 (0.59) 200 (0.41) 0.63 (0.43,0.91) 0.016
NR 512 (0.54) 436 (0.46)
CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.
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(VEFGA, VEGFC, FIGF, and FLT4)
was retrieved from the dbSNP (build
119, http://www.ncbi.nlm.nih.gov/SNP).
Those SNPs were genotyped for 48
independent typical Koreans (data not
shown). On the basis of this genotype
result, we selected 31 SNPs (6 in
VEGFA, 3 in VEGFC, 2 in FIGF
(VEGFD), and 20 in FLT4) for further
genotyping of 717 case–control samples
(Figure 1, Table 1). The rs10085109 in
FLT4, which showed Hardy–Weinberg
dysequilibrium in the normal controls,
was not analyzed. The SNP selection
was performed using the Tagger pro-
gram (http://www.broad.mit.edu/mpg/
tagger) and the linkage disequilibrium
(LD) bin approach (Carlson et al.,
2004). Genotype identification was
performed with the GenomeLab
SNPstream (ultrahigh-throughput sys-
tem; Bell et al., 2002). Further details
about the genotyping procedure were
described in our previous report (Kim
et al., 2007). The average genotyping
success rate was 98.80%. The statistical
significance of the allelic effect and the
genotypic effect of SNPs on psoriasis
were tested using logistic regression
analysis, whereas age and gender were
used as controlling covariates. To de-
termine the significance of the geno-
typic effect, P-values of the type III
effect of genotypes were used and the
odds ratios for the genotypes were
calculated during the analysis. Men
and women were analyzed separately
for SNPs in the X-linked gene FIGF.
Haplotype associations were tested
using haplo.score, which was devel-
oped by Schaid et al. (2002), whereas
age and gender were used as control-
ling covariates.
From this experiment, two SNPs
from FLT4 showed significant associa-
tions with psoriasis (Table 2a and b).
The rs3776413 resulted in a significant
P-value of 0.028 on the allelic effect
test, but not on the genotypic effect test
(P¼0.09). The odds ratio of A allele
was 1.61 (95% confidence interval:
1.05–2.47). The rs307823 resulted in
significant P-values on both allelic and
genotypic effect tests (P¼0.016 and
0.041, respectively). The odds ratio of A
allele was 0.63 (95% confidence inter-
val: 0.43–0.91). The rs3776413 and
rs307823 were in an LD block by
Gabriel’s block definition in the Haplo-
View software (Barrett et al., 2005). The
haplotypes in the LD block of the four
adjacent SNPs (rs3776413, rs3736062,
rs307823, and rs3797104) showed
that the haplotype GCAA may decrease
the odds of psoriasis (P¼0.009, simu-
lation P¼0.006) and ACGA may
increase the odds of psoriasis (P¼
0.049, 0.048) (Table 2c). To test for
the association of the SNPs and the
serum FLT4 levels, the FLT4 protein was
assayed for 42 psoriasis and 45 normal
samples with using an ELISA kit
(R&D systems, Minneapolis, MN). On
the two-way analysis of variance, the
genotypes for rs307823 did not show
a significant effect on the serum
FLT4 levels (P¼0.46). However, the
group variables of the psoriasis and
normal controls showed significant
results (P¼0.01), and the average
serum FLT4 level was higher in the
psoriasis (14,541±439) than that in
the normal controls (12,456±624)
(Table 2d).
Table 2b. Genotype frequencies of the rs3776413 and rs307823 SNPs in the FLT4 gene between the psoriasis and
normal control groups while adjusting for age and gender
Genotype OR (95% CI)
SNP Group GG GA AA GA vs GG AA vs GG P-value1
rs3776413 PS 150 (0.62) 83 (0.34) 10 (0.04) 1.68 (0.98,2.86) 2.34 (0.7,7.81) 0.09
NR 341 (0.72) 121 (0.26) 12 (0.03)
rs307823 PS 75 (0.31) 132 (0.55) 34 (0.14) 0.78 (0.45,1.34) 0.34 (0.15,0.79) 0.041
NR 130 (0.27) 252 (0.53) 92 (0.19)
CI, confidence interval; NR, normal; OR, odds ratio; PS, psoriasis; SNP, single-nucleotide polymorphism.
1P-value of the type III effect of the genotype.
Table 2c. The haplotype association test for the FLT4 gene with psoriasis
Haplotype Frequency Haplo.score P-value Simulation P-value
GCAA 0.438 2.607 0.009 0.006
GTGA 0.126 0.054 0.957 0.94
GCGG 0.258 1.016 0.31 0.274
ACGA 0.162 1.968 0.049 0.048
Four loci (rs3776413, rs3736062, rs307823, and rs3797104) haplotypes showed significant
association. The test was performed using haplo.score with haplotypes of the minor allele frequencies
greater than 0.01.
Table 2d. The average concentrations of serum FLT4 protein (pgml1)
among the two groups according to the rs307823 genotype
Genotype NR (n=45) PS (n=42)
GG 13,838±740 (n=15) 13,992±677 (n=17)
GA 11,465±1,078 (n=20) 15,383±615 (n=18)
AA 12,364±1,357 (n=10) 13,712±1,273 (n=7)
Total 12,456±624 14,541±439
NR, normal; PS, psoriasis.
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Although the individual SNPs in the
VEGFA gene did not show any significant
association, haplotype GC of rs3025033
and rs3025035, which are in a LD block,
showed marginally significant effect on
the odds of psoriasis (P¼ 0.068, simula-
tion P¼0.045) (Table 3).
Through our experiments, we found
significant correlations between the
haplotype GC of two SNPs in the
VEGFA gene and psoriasis without any
of the associated SNPs from the pre-
vious reports, and this can be explained
by population stratification. We also
demonstrated that two SNPs and the
haplotypes in the FLT4 gene are
strongly associated with the susceptibi-
lity to psoriasis, and to our knowledge
this is unreported before. Although the
serum FLT4 concentrations were higher
in the psoriasis than those in the normal
control, they were not correlated with
the FLT4 polymorphism.
The human FLT4 gene is essential for
the vascular development during em-
bryogenesis (Olsson et al., 2006) and it
is almost exclusively found in the
lymphatic endothelium in adults (Iljin
et al., 2001). FLT4 is activated by its
specific ligand VEGFC, and correlations
between mRNA and the protein levels
of FLT4 and ligands were reported in
different cells and tissues (Hanrahan
et al., 2003; Schietroma et al., 2003).
Therefore, it is tempting to expect
associations of VEGFC or VEGFD with
psoriasis, yet we could not find any
SNPs of those genes in psoriasis, and it
is hard to speculate how FLT4 is
regulated in psoriasis or whether FLT4
is associated with VEGFA. Neverthe-
less, the facts that enlarged tortuous
blood and lymphatic vessels were
found only in the lesional skin of
psoriasis (Kunstfeld et al., 2004) and
that the psoriatic phenotype was
observed in VEGFA transgenic mice
(Detmar et al., 1998; Kunstfeld et al.,
2004) suggested that VEGFA and FLT4
maybe indirectly related in the patho-
genesis of psoriasis. A possible specula-
tion is that VEGFA may indirectly
attract the inflammatory cells produ-
cing VEGFC and VEGFD, which bind to
FLT4. Further studies are needed to
elucidate the possible interaction be-
tween VEGFA and FLT4.
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